This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: GenVec

BOSTON ( TheStreet) -- The Biotech Stock Mailbag Readers' Portfolio (BSMRP) made its debut yesterday with 20 stocks selected by you, the readers of this Mailbag column. Thanks again for all the great nominations -- I look forward to writing about the performance of the BSMRP in future columns.

As of last night's close, the BSMRP was up 1.3%. Still way too early to say much more than that, but I hope you agree that the portfolio is reasonably diverse and encompasses stocks that should bring big news, one way or the other, this year.

One thing in particular that I like is that the BSMRP includes stocks I favor, such as Vertex Pharmaceuticals (VRTX), Dendreon (DNDN), Allos Therapeutics (ALTH) and ImmunoGen (IMGN), as well as stocks which I've not looked so kindly upon, like Cell Therapeutics (CTIC) and Geron (GERN). This is a portfolio chosen by readers, not me, so we'll see how it plays out over the next 12 months.

Once again, you can read all about the BSMRP's 20 stocks right here.

Onward to this week's emails.
1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANX $0.73 0.00%
DNDN $0.06 -6.02%
ALKS $32.17 0.00%
CYCC $0.36 0.00%
EXAS $6.28 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs